BiotechTube
Antibiotice

Antibiotice

Iași, Europe - Other· Est.
antibiotice.ro
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Antibiotice is a well-established, revenue-generating Romanian generic drug manufacturer with a significant international footprint. The company is executing a major 75 million euro investment to develop an R&D and production center for critical medicines, signaling a strategic expansion. It maintains strong regulatory standing with multiple FDA approvals and eight GMP-certified lines, positioning it as a reliable partner in the global generic pharmaceuticals market.

Anti-infectivesCardiovascularOncologyCentral Nervous System (CNS)

Technology Platform

Integrated GMP-certified manufacturing infrastructure with 8 production lines, specializing in API and finished dose form production for generic drugs, including sterile injectables and topical products. FDA-approved facilities and an Integrated Management System for Quality, Environment, and Safety.

Opportunities

The 75 million euro investment in a new R&D and production center for critical medicines positions the company to capture a high-value niche in the generics market, reducing vulnerability to shortages.
Continued FDA approvals and successful tenders in large public health systems like the UK's NHS provide clear pathways for geographic and product expansion.

Risk Factors

Intense price competition in the global generic drug market threatens margins.
Significant regulatory risk exists, as maintaining GMP certifications from stringent agencies like the FDA is mandatory for operations.
The large-scale STEP investment program carries execution risk related to costs, timelines, and market acceptance of the new capacity.

Competitive Landscape

Antibiotice competes in the highly fragmented global generic pharmaceuticals market against large multinational generics firms (e.g., Teva, Sandoz) and numerous regional players. Its competitive edge is derived from its modern, FDA-approved manufacturing infrastructure, focus on complex products like sterile injectables and APIs, and its strategic positioning as a reliable European manufacturer investing in next-generation capacity for critical medicines.

More companies in Small Molecule Drugs →More companies in Europe - Other →